Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Finished Goods (2019 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Finished Goods for 7 consecutive years, with $30.6 million as the latest value for Q3 2025.

  • Quarterly Finished Goods fell 4.13% to $30.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $30.6 million through Sep 2025, down 4.13% year-over-year, with the annual reading at $29.2 million for FY2024, 4.08% up from the prior year.
  • Finished Goods for Q3 2025 was $30.6 million at Xtant Medical Holdings, down from $31.2 million in the prior quarter.
  • The five-year high for Finished Goods was $31.9 million in Q3 2024, with the low at $10.6 million in Q2 2022.
  • Average Finished Goods over 5 years is $20.7 million, with a median of $16.3 million recorded in 2021.
  • The sharpest move saw Finished Goods plummeted 31.46% in 2022, then soared 158.62% in 2024.
  • Over 5 years, Finished Goods stood at $11.8 million in 2021, then decreased by 7.67% to $10.9 million in 2022, then soared by 158.35% to $28.1 million in 2023, then increased by 4.08% to $29.2 million in 2024, then increased by 4.72% to $30.6 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $30.6 million, $31.2 million, and $30.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.